Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 245

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 245
---
analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below
any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors,
the price of our Common Stock could decline substantially. Such a stock price decline could occur even when we have met any previously
publicly stated revenue and/or earnings guidance we may provide.

Anti-takeover provisions under our organizational
documents and Delaware law could delay or prevent a change of control which could limit the market price of our Common Stock and may prevent
or frustrate attempts by our stockholders to replace or remove our then-current management.

Our Charter and Bylaws, contain
provisions that could delay or prevent a change of control of our board of directors that our stockholders might consider favorable. Some
of these provisions include:

●a
                                            board of directors divided into three classes serving staggered three-year terms, such that
                                            not all members of the board of directors will be elected at one time;

●a
                                            prohibition on stockholder action through written consent, which requires that all stockholder
                                            actions be taken at a meeting of our stockholders;

●a
                                            requirement that special meetings of stockholders be called only by the chairperson of our
                                            board of directors, our Chief Executive Officer or by a majority of the total number of authorized
                                            directors;

●a
                                            requirement that no member of our board of directors may be removed from office by our stockholders
                                            except for cause and, in addition to any other vote required by law and subject to the rights
                                            of the holders of any series of preferred stock to elect additional directors under specified
                                            circumstances, upon the approval of not less than two-thirds of all outstanding shares of
                                            our voting stock then entitled to vote in the election of directors;

●a
                                            requirement of approval of not less than two-thirds of all outstanding shares of our voting
                                            stock to amend any bylaws by stockholder action or to amend specific provisions of our Charter;
                                            and

●the
                                            authority of the board of directors to issue preferred stock on terms determined by the board
                                            of directors without stockholder approval and which preferred stock may include rights superior
                                            to the rights of the holders of Common Stock.

90

In addition, because we are
incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which may prohibit certain